Fenfluramine low dose - Zogenix

Drug Profile

Fenfluramine low dose - Zogenix

Alternative Names: Brabafen; Fintepla; Low-dose fenfluramine; ZX-008

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Brabant Pharma
  • Developer Brabant Pharma; Zogenix
  • Class Amphetamines; Anorectics; Antiepileptic drugs; Small molecules
  • Mechanism of Action Serotonin receptor agonists; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome; Dravet syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dravet syndrome
  • Phase II Lennox-Gastaut syndrome
  • Preclinical Epilepsy

Most Recent Events

  • 29 Sep 2017 Zogenix announces intention to submit regulatory applications in USA and Europe Dravet syndrome in second half of 2018
  • 29 Sep 2017 Merged efficacy and adverse events data from two phase III trials in Dravet Syndrome released by Zogenix
  • 23 Aug 2017 Zogenix International initiates enrolment in a phase III trial for Dravet Syndrome (In childrens, In adolescents) in USA (NCT03299842)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top